ClinicalCodes.org
An online clinical codes repository to improve validity and reproducibility of medical database research
Research article:
HbA1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: a nested case-control study
Reference:
Victor W. Zhong; Juhaeri Juhaeri; Stephen R. Cole; Christina M. Shay; Penny Gordon-Larsen; Evangelos Kontopantelis; Elizabeth J Mayer-Davis(2017) HbA1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: a nested case-control study. Journal of Diabetes and its Complications, doi: http://dx.doi.org/10.1016/j.jdiacomp.2017.10.008
- Link to article
- Abstract
- Aims: To determine association between HbA1C variability and hypoglycemia requiring hospitalization (HH) in adults with type 1 diabetes (T1D) and type 2 diabetes (T2D). Methods: Using nested case-control design in electronic health record data in England, one case with first or recurrent HH was matched to one control who had not experienced HH in incident T1D and T2D adults. HbA1C variability was determined by standard deviation of ≥3 HbA1C results. Conditional logistic models were applied to determine association of HbA1C variability with first and recurrent HH. Results: In T1D, every 1.0% increase in HbA1C variability was associated with 90% higher first HH risk (95% CI, 1.25-2.89) and 392% higher recurrent HH risk (95% CI, 1.17- 20.61). In T2D, a 1.0% increase in HbA1C variability was associated with 556% higher first HH risk (95% CI, 3.88-11.08) and 573% higher recurrent HH risk (95% CI, 1.59-28.51). In T2D for first HH, the association was the strongest in non-insulin non-sulfonylurea users (P<0.0001); for recurrent HH, the association was stronger in insulin users than sulfonylurea users (P=0.07). The HbA1C variability-HH association was stronger in more recent years in T2D (P≤0.004). Conclusions: HbA1C variability is a strong predictor for HH in T1D and T2D.
- Author for correspondence
- Elizabeth J Mayer-Davis
- Email for correspondence
- mayerdav@email.unc.edu
Code list: res50: DPP-4 inhibitors
24 codes in list
| Code | Coding system | Description | Entity type | List name | drugsubstance | bnfcode | bnfchapter |
|---|---|---|---|---|---|---|---|
| 35022 | CPRD_product_code | Sitagliptin 100mg tablets | drug | res50: DPP-4 inhibitors | Sitagliptin phosphate | 6010203 | Other Antidiabetic Drugs |
| 35462 | CPRD_product_code | Januvia 100mg tablets (Merck Sharp & Dohme Ltd) | drug | res50: DPP-4 inhibitors | Sitagliptin phosphate | 6010203 | Other Antidiabetic Drugs |
| 37874 | CPRD_product_code | Vildagliptin 50mg / Metformin 850mg tablets | drug | res50: DPP-4 inhibitors | Metformin Hydrochloride/vildagliptin | 6010203 | Other Antidiabetic Drugs |
| 37875 | CPRD_product_code | Vildagliptin 50mg tablets | drug | res50: DPP-4 inhibitors | Vildagliptin | 6010200 | Antidiabetic Drugs |
| 37902 | CPRD_product_code | Vildagliptin 50mg / Metformin 1g tablets | drug | res50: DPP-4 inhibitors | Metformin hydrochloride/Vildagliptin | 6010203 | Other Antidiabetic Drugs |
| 38551 | CPRD_product_code | Eucreas 50mg/1000mg tablets (Novartis Pharmaceuticals UK Ltd) | drug | res50: DPP-4 inhibitors | Metformin hydrochloride/Vildagliptin | 6010203 | Other Antidiabetic Drugs |
| 39149 | CPRD_product_code | Galvus 50mg tablets (Novartis Pharmaceuticals UK Ltd) | drug | res50: DPP-4 inhibitors | Vildagliptin | 6010200 | Antidiabetic Drugs |
| 39203 | CPRD_product_code | Eucreas 50mg/850mg tablets (Novartis Pharmaceuticals UK Ltd) | drug | res50: DPP-4 inhibitors | Metformin hydrochloride/Vildagliptin | 6010203 | Other Antidiabetic Drugs |
| 41204 | CPRD_product_code | Saxagliptin 5mg tablets | drug | res50: DPP-4 inhibitors | Saxagliptin hydrochloride | 6010203 | Other Antidiabetic Drugs |
| 41431 | CPRD_product_code | Onglyza 5mg tablets (AstraZeneca UK Ltd) | drug | res50: DPP-4 inhibitors | Saxagliptin hydrochloride | 6010203 | Other Antidiabetic Drugs |
| 43619 | CPRD_product_code | Metformin 1g / Sitagliptin 50mg tablets | drug | res50: DPP-4 inhibitors | Sitagliptin phosphate/Metformin hydrochloride | 6010203 | Other Antidiabetic Drugs |
| 43684 | CPRD_product_code | Janumet 50mg/1000mg tablets (Merck Sharp & Dohme Ltd) | drug | res50: DPP-4 inhibitors | Sitagliptin phosphate/Metformin hydrochloride | 6010203 | Other Antidiabetic Drugs |
| 45775 | CPRD_product_code | Saxagliptin 2.5mg tablets | drug | res50: DPP-4 inhibitors | Saxagliptin hydrochloride | 6010203 | Other Antidiabetic Drugs |
| 45821 | CPRD_product_code | Onglyza 2.5mg tablets (AstraZeneca UK Ltd) | drug | res50: DPP-4 inhibitors | Saxagliptin hydrochloride | 6010203 | Other Antidiabetic Drugs |
| 46665 | CPRD_product_code | Linagliptin 5mg tablets | drug | res50: DPP-4 inhibitors | Linagliptin | 6010203 | Other Antidiabetic Drugs |
| 46716 | CPRD_product_code | Trajenta 5mg tablets (Boehringer Ingelheim Ltd) | drug | res50: DPP-4 inhibitors | Linagliptin | 6010203 | Other Antidiabetic Drugs |
| 48401 | CPRD_product_code | Sitagliptin 50mg tablets | drug | res50: DPP-4 inhibitors | Sitagliptin phosphate | 6010203 | Other Antidiabetic Drugs |
| 48533 | CPRD_product_code | Sitagliptin 25mg tablets | drug | res50: DPP-4 inhibitors | Sitagliptin phosphate | 6010203 | Other Antidiabetic Drugs |
| 50087 | CPRD_product_code | Januvia 50mg tablets (Merck Sharp & Dohme Ltd) | drug | res50: DPP-4 inhibitors | Sitagliptin phosphate | 6010203 | Other Antidiabetic Drugs |
| 50124 | CPRD_product_code | Januvia 25mg tablets (Merck Sharp & Dohme Ltd) | drug | res50: DPP-4 inhibitors | Sitagliptin phosphate | 6010203 | Other Antidiabetic Drugs |
| 54150 | CPRD_product_code | Jentadueto 2.5mg/850mg tablets (Boehringer Ingelheim Ltd) | drug | res50: DPP-4 inhibitors | Linagliptin/Metformin hydrochloride | 06010202/06010203 | Biguanides/Other Antidiabetic Drugs |
| 54891 | CPRD_product_code | Saxagliptin 2.5mg / Metformin 1g tablets | drug | res50: DPP-4 inhibitors | Metformin hydrochloride/Saxagliptin hydrochloride | 6010203 | Other Antidiabetic Drugs |
| 56965 | CPRD_product_code | Komboglyze 2.5mg/1000mg tablets (AstraZeneca UK Ltd) | drug | res50: DPP-4 inhibitors | Metformin hydrochloride/Saxagliptin hydrochloride | 6010203 | Other Antidiabetic Drugs |
| 59809 | CPRD_product_code | Alogliptin 6.25mg tablets | drug | res50: DPP-4 inhibitors | Alogliptin benzoate | 6010200 | Antidiabetic Drugs |
Please log in to leave a comment.
Code list links:
ClinicalCodes is a project at the University of Manchester Institute of Population Health
The ClinicalCodes project is funded by the National Institute for Health Research (NIHR) School for Primary Care Research (SPCR)